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Herpes simplex virus-1 (HSV-1) is a relatively large double-stranded DNA virus
encoding at least 89 proteins with well characterized disease pathology. An under-
standing of the functions of viral proteins together with the ability to genetically engineer
specific viral mutants has led to the development of attenuated HSV-1 for gene therapy.
This review highlights the progress in creating attenuated genetically engineered HSV-1
mutants that are either replication competent (viral non-essential gene deleted) or
replication defective (viral essential gene deleted). The choice between a replication-
competent or -defective virus is based on the end-goal of the therapeutic intervention.
Replication-competent HSV-1 mutants have primarily been employed as antitumor
oncolytic viruses, with the lytic nature of the virus harnessed to destroy tumor cells
selectively. In replacement gene therapy, replication-defective viruses have been utilized
as delivery vectors. The advantages of HSV-1 vectors are that they infect quiescent and
dividing cells efficiently and can encode for relatively large transgenes.
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Gene therapy utilizing genetically engineered
herpes simplex virus-1 (HSV-1) is under active
investigation for the treatment of both cancer
and somatic diseases. Wild-type HSV-1, however,
is a highly pathogenic virus. Following replication
at the portal of entry (mucosal epithelial tissue)
with subsequent lysis of the infected cell, the virus
infects sensory neurons (neuroinvasion) and is
transported retrogradely to the nucleus of the
neuron. Here the virus enters either a lytic or latent
state. The lytic cycle (neurovirulence) is character-
ized by productive viral infection with the release
of progeny virions, and, in the worst case, causes
fatal encephalitis. Establishing latency in sensory
ganglia is a hallmark of HSV infection; however,
this process is poorly understood. In the latent
state, the viral DNA remains extrachromosomal;
the only transcribed RNA appears to be that of the
latency-associated transcripts (LATs). These bio-
logical properties of wild-type HSV-1 have also
made it a focus of intense study for gene therapy
applications. Its ability to destroy cells in the lytic
cycle has been exploited for cancer therapy with
attenuated replication-competent HSV-1. Its trop-
ism for neuronal cells (i.e. postmitotic cells) has
been harnessed for treating neurodegenerative
diseases, and especially intriguing in this treat-
ment paradigm is its ability to peacefully coexist
within the neuron in a latent state and transcribe
the LAT gene. Theoretically, the large transgene
coding capacity of HSV-1 also offers advantages
over other viruses, as it can be a vector for the
delivery of relatively large foreign genes.
HSV-1 is an enveloped, double-stranded DNA
virus with a viral genome of 152 kb encoding at
least 84 polypeptides [1]. The genome has two
unique stretches, the unique long (UL) and unique
short (US) segments, separated by terminal
inverted repeats. Genes have traditionally been
classified as essential or non-essential, depending
upon their requirement for viral replication in cell
culture. However, even the non-essential genes
play an important role in HSV-1 replication within
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its natural host. Viral gene expression occurs in a
temporal cascade, with immediate early (a) genes
expressed first, followed by early (b) and then late
(g) gene expression. The products of a genes are
infected cell proteins 0 (ICP0), ICP4, ICP22, ICP27,
and ICP47, and are primarily involved in tran-
scriptional regulation. b gene products are invol-
ved in viral DNA replication, and g gene products
primarily encode structural proteins.
The use of genetically engineered HSV-1 for
gene therapy involves either replication-compe-
tent or replication-defective HSV-1 mutants. Repli-
cation-competent viruses have deletions in non-
essential genes that attenuate the virus such that
replication is dependent on the type of cell that the
virus infects. For example, replication-competent
HSV-1 mutants for tumor therapy selectively repli-
cate more efficiently in tumor cells than in normal
cells. Replication-defective HSV-1 mutants are
deleted in one or more essential genes and there-
fore are unable to enter the replication program.
The use of replication-competent or -defective
HSV-1 mutants for gene therapy applications
depends on the goal of therapy. For cancer ther-
apy, replication-competent HSV-1 mutants have
provided a powerful tool for tumor cell destruc-
tion. In the therapy of neurodegenerative diseases,
the construction of replication-defective HSV-1
mutants that encode and deliver protective genes
without cell destruction has been studied in
experimental models.
A T T E N U A T E D R E P L I C A T I O N -
C O M P E T E N T H S V - 1 F O R
C A N C E R T H E R A P Y
The concept of viral lysis of tumor cells has been
discussed for more than a century [2]. Viral onco-
lysis is based on a simple yet elegant approach to
cancer treatment. A principle consequence of the
replicative cycle of selected viruses is cell lysis
with subsequent spread to and lysis of adjacent
tumor cells. In theory, infection of a single cancer
cell within a tumor initiates a self-sustaining chain
reaction resulting in infection and cell death
throughout the tumor. The key to such an ap-
proach is genetically engineering viral attenuation
such that the virus is predisposed to replicate in
cancer cells but not the adjacent normal tissue.
Replication-competent, attenuated HSV and ade-
novirus as well as reovirus are currently being
employed as such antitumor agents [3–5].
The central tenet of this approach is the ability to
create a virus that targets tumor cells for death and
not the non-transformed adjacent cells. Theoreti-
cally, this problem can be addressed at multiple
points during the virus life cycle, beginning with
the attachment of the virus to the target cell. Upon
entering the cell, the lytic program of the virus can
be controlled by the intracellular environment
such that it replicates within rapidly dividing cells
(i.e. tumor cells) but not normal tissue. Further
specificity can be obtained for specific histologic
types of tumor through the construction of engi-
neered viruses with virus essential genes linked to
tumor-type-specific enhancer/promoter elements.
These technical hurdles,whilecomplex,havebegun
to be resolved with the molecular understanding
of both cancer cells and the many genes of HSV-1.
Targeted viral entry
The simplest way to achieve tumor cell specificity
involves altering the way the virus recognizes cells
(i.e. receptor-mediated binding and fusion). This
involves retargeting the virus so that it binds only
to tumor cell-specific receptors. This approach has
not currently been undertaken with replication-
competent HSV. However, recent years have seen
much advancement in the understanding of the
mechanism of HSV-1 entry into cells, which can be
exploited to target HSV-1 entry to tumor cells [6,7].
Targeting proliferating cells
One method of obtaining replication-conditional
HSV-1 is to create viral mutants that have deletions
that can be complemented by certain cells. Certain
viral genes encode proteins that have cellular
homologs and therefore could be complemented
by the tumor cell. The use of HSV-1 as an anti-
glioma agent provides a case study for this type of
approach. Glioma cells grow in an environment
surrounded by quiescent neurons. HSV-1 selectiv-
ity for gliomas is achieved by exploiting the dif-
ferences between the intracellular milieu of
dividing glioma cells and that of quiescent neu-
rons. HSV-1 encodes multiple genes involved
in viral DNA replication as well as nucleotide
precursor production. These genes include viral
thymidine kinase and the large subunit of ribonu-
cleotide reductase [1]. Such genes may be neces-
sary for wild-type virus to efficiently replicate
in cells where deoxynucleotide pools are low
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(e.g. quiescent neurons). However, tumor cells
may have large pools of deoxynucleotides that
the virus can scavenge to replicate its DNA. Thus,
deletion of viral genes involved in DNA synthesis
has provided a rational basis to create genetically
engineered HSV-1 as an anticancer agent.
Based on this rationale, the HSV-1 viral mutant
dlsptk containing a deletion in the gene encoding
thymidine kinase was initially shown to have
efficacy against experimental gliomas [3]. How-
ever, deletion of viral thymidine kinase has the
drawback of removing the ability to treat adverse
effects of infection, should they occur in patients,
with acyclovir. Using an analogous strategy, an
HSV-1 viral mutant hrR3 containing the Escherichia
coli lacZ gene inserted within the gene encoding
the large subunit of ribonucleotide reductase
(UL39) was utilized for experimental glioma ani-
mal models [8]. This virus has the advantage of
being ten-fold more sensitive to both acyclovir and
ganciclovir. Furthermore, the expression of the
lacZ gene allows detection of the virus within
histologic sections of the tumor. In a similar
approach, HSV-1 with a deletion of the UL2 gene
encoding uracil DNA glycosylase was shown to
have efficacy against tumor xenografts as well as
ganciclovir hypersensitivity [9]. These initial
studies have spawned much interest in the use
of replication-conditional HSV-1 as antiglioma
agents and more broadly as antitumor agents for
a wide variety of tumors. However, many normal
tissues also have high mitotic indices, and such
viruses may not discriminate between rapidly
proliferating normal and cancer cells.
Creating a non-neurovirulent
replication-competent HSV-1
The discovery of an HSV-1 gene associated with
neurovirulence has provided further impetus for
the use of replication-conditional HSV-1 for can-
cer. Deletion of the g134.5 gene, present in two
copies in the long repeat regions, reduced neuro-
virulence by greater than five orders of magni-
tudes upon direct intracranial inoculation in mice
[10]. In response to viral infections, cells activate
RNA-dependent protein kinase (PKR), which
phosphorylates the a subunit of translation initia-
tion factor 1 (eIF-2a). Phosphorylated eIF-2a blocks
the translation of mRNA, and thus provides an
innate host defense mechanism against viral infec-
tion. HSV-1 has evolved a rather curious mechan-
ism to deal with PKR activation. The product of the
g134.5 viral gene binds to protein phosphatase-1,
resulting in dephosphorylation of eIF-2a, and pre-
cluding host protein synthesis shut-off [11]. Given
that HSV-1 deleted in g134.5 (R3616) is severely
attenuated for neurovirulence, this virus is an ideal
candidate for tumor therapy within the central
nervous system (CNS). Subsequently, R3616 has
been shown to be safe and also effective in intra-
cranial glioma and xenograft models [12,13].
However, viruses deleted for g134.5 replicate
sluggishly and are not genetically stable upon
serial passage in cell culture, since second-site
mutations in this virus that overcome the protein
synthesis shut-off characteristic of g134.5 viral
mutants have been isolated [14]. One compensatory
second-site mutation in HSV-1 lacking g134.5 is
located in the US11–12 region [15]. The US11 gene is
normally expressed as a late gene with g2 kinetics,
whereas the US12 gene (ICP47) is expressed with
immediate early (a) kinetics [1]. Viral mutants that
link the US11 gene with the US12 promoter express
US11 with immediate early kinetics rather than g2
kinetics. When US11 is expressed earlier, it is
effective in compensating for the deletion in
g134.5, in that eIF-2a is not phosphorylated and
protein translation does not cease [16,17].
There are at least two phenotypes associated
with g134.5-deleted HSV-1, eIF-2a phosphoryla-
tion and decreased neurovirulence. If these phe-
notypes are the result of distinct functions of
g134.5, then it may be possible to prevent eIF-2a
phosphorylation by expressing US11 with immedi-
ate early kinetics in a g134.5-null virus while still
retaining decreased neurovirulence. Predictably,
such a virus would replicate more efficiently
within tumor cells (since protein translation is
not blocked) and would result in enhanced tumor
regression. Recent evidence supports this hypoth-
esis. Viruses containing deletions in g134.5 and
expressing US11 from the US12 promoter repli-
cated nearly as efficiently as wild-type virus in
tumor cell lines that fail to support appreciable
growth of the g134.5-null virus. The extent of
replication correlated with enhanced tumor xeno-
graft regression [18,19]. Importantly, this virus still
retained the non-neurovirulent phenotype in mice
associated with the g134.5-null virus, and it may
serve as a more successful oncolytic agent. How-
ever, serial passage of g134.5-null mutant virus in
human cells yielded additional second-site com-
pensatory mutants that were able to synthesize
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viral proteins and exhibited increased neuroviru-
lence [20]. It is likely that serial passage of g134.5-
null mutants in the central nervous system would
also select for heightened neurovirulence.
Transcriptional targeting of tissue-specific cells
As mentioned above, some normal tissues have
mitotic indices that rival those of tumors. Thus,
another approach to target tissue-specific tumor
cells has been recently explored. Transcriptional
differences exist between different organs as well
as between tumor and normal cells of the same
organ. Identifying specific cell gene products tran-
scriptionally upregulated in cell types allows for
the generation of engineered HSV-1 mutants that
contain such promoter/enhancer elements up-
stream of essential viral genes. Such a strategy
restricts viral replication to cells that contain tran-
scription factors to drive the expression of the
chimeric cellular promoter/viral essential gene.
Studies have shown that such an approach is
feasible with the a4 gene of HSV-1. The a4 gene
exists in two copies in the HSV-1 unique short
repeat regions, is essential in cell culture, and is
expressed immediately after infection [1]. Infected
cell protein number 4 (ICP4), the product of the a4
gene, is a major viral regulatory protein and trans-
activator. The HSV-1 viral mutant d120 contains
deletions in both copies of ICP4, but results in
apoptosis upon infection of cells [21,22]. To target
albumin-expressing cells, virus G92A was created
by placing the a4 gene under the transcriptional
control of the albumin enhancer and promoter
elements and inserting it into d120 [23]. While
wild-type HSV-1 replicated efficiently irrespective
of albumin expression, virus G92A replicated 3 log
more efficiently in albumin-expressing cell lines
than in non-albumin-expressing cell lines. How-
ever, G92A replicated more slowly than wild-type
HSV-1, which in part is due to the delayed
accumulation of ICP4 in G92A-infected cells as
compared to wild-type infected cells. Importantly,
G92A was also shown to selectively inhibit tumor
xenograft growth of albumin-expressing cells (i.e.
hepatomas) in animal models compared to non-
albumin-expressing tumor xenografts (PC-3 or
HeLa) [24]. There was no apparent HSV-1 toxicity
in mice intrahepatically injected with G92A. The
problem with this approach is that albumin is
transcriptionally expressed in the normal adult
liver, indicating that normal liver cells may
support the replication of G92A by expression of
ICP4 from the albumin enhancer/promoter ele-
ments, with resultant destruction of normal liver
cells. A similar approach for targeting soft tissue
and bone tumors through the use of the human
calponin promoter driving the expression of the
a4 gene in a d120-based virus has been reported
[25]. Calponin mRNA and protein are aberrantly
expressed in a variety of human soft tissue and
bone tumors; these tumor cells could support the
replication of such a virus, resulting in tumor-
type-specific oncolysis.
With the advent of gene microarrays, it is fea-
sible to quickly screen and identify genes that
are transcriptionally upregulated in tumor cells
compared to normal tissue. By using the above-
mentioned technique, tumor-type-specific HSV-1
could be tailored for individual tumor histologies.
However, such a strategy requires that multiple
viruses be created and driven by tissue/tumor-
specific promoters. Also, since tumors consist of a
heterogeneous population of cells, specific promo-
ter elements may not be active in all the cancer
cells. Finally, leaky enhancer/promoter elements
may allow replication in non-targeted cells.
Replication-competent HSV-1 in clinical
cancer trials
With a wealth of preclinical studies having been
done with replication-competent, genetically engi-
neered HSV-1 over the last decade, such constructs
have entered clinical trials. Safety is of utmost
concern in using replication-competent viruses,
since wild-type HSV has been the cause of disease
since ancient times, particularly life-threatening
encephalitis. To date, at least three phase I clinical
trials have been completed or are underway
using replication-competent, genetically engineer-
ed HSV-1 for tumor therapy. Three different
attenuated HSV-1 viruses were used in each of
these studies and are identified as 1716, G207, and
NV1020 (R7020). Both 1716 and G207 have com-
pleted phase I trials in patients with recurrent
gliomas in the UK and the USA, respectively.
NV1020 is currently undergoing phase I trials in
patients with liver metastases from adenocarci-
noma of the colon.
1716 and G207
Glioblastoma multiforme (GBM) is the most
common and aggressive primary brain tumor.
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Characteristics of this tumor make it an ideal candi-
date for experimental therapy. First, the median
survival from diagnosis is 1 year with such con-
ventional treatments as surgery and external beam
radiotherapy. Second, treatment failure is local, in
that 90% of patients have tumor recurrence within
2 cm of the initial lesion, and metastases (systemic
spread) are rare. Given the rapid mortality and
local therapy failure, GBM was the first tumor to
be tested with genetically engineered HSV-1. HSV-
1 deleted in both copies of g134.5 is significantly
neuroattenuated and resulted in the regression of
experimental brain tumors in animal models
[10,12,13,26]. This construct with the addition of
a mutation in the ribonucleotide reductase gene
provides the construct for G207, which was the
basis for a phase I clinical trial in the USA [27].
G207 (strain F derived) is deleted in both copies of
g134.5 and has a lacZ insertion in the UL39 gene that
inactivates the large subunit of ribonucleotide
reductase (ICP6). The g134.5 deletion renders the
virus non-neurovirulent (identical to 1716), and
inactivation of ICP6 targets the virus to replicate in
proliferating cells. For safety reasons, it may be
beneficial to create attenuated viruses that are
multimutated to reduce the probability of sec-
ond-site mutations that can restore functions of
deleted genes, as exemplified by altered expres-
sion of US11 complementing the protein synthesis
shut-off phenotype of g134.5. G207 has been
repeatedly found to have oncolytic activity against
a variety of tumor histologies, and its safety has
been characterized in Aotus nancymae (New World
owl monkeys) by intracerebral inoculation at
doses up to 109 PFU [27–30]. Twenty-one patients
with malignant glioma were enrolled in a dose-
escalating study with G207, starting at 106 PFU and
rising to 3 109 PFU [31]. No patients developed
HSV encephalitis or adverse toxicity directly
ascribed to G207 following intratumoral inocula-
tion of G207, even at the highest dose. An HSV-1-
seronegative patient treated at the highest dose did
seroconvert. Tissue samples from two patients
were positive for HSV-1 and lacZ by PCR, indicat-
ing the presence of G207.
The genetically engineered HSV-11716 (strain 17
derived) is deleted in both copies of g134.5 [32]. A
phase I clinical trial has been completed in Glas-
gow, assessing the safety of 1716 upon intratu-
moral inoculation in nine patients with relapsed
GBM [33]. Groups of three patients received 103,
104 or 105 PFU by stereotactic intratumoral injec-
tion. No evidence of encephalitis, reactivation of
HSV-1 or adverse clinical outcomes was seen in
this clinical trial. Tissue samples following viral
inoculation were available from three of the
patients who underwent subsequent tumor resec-
tion. The earliest time was 3.5 weeks postinocula-
tion. Unfortunately, immunohistochemistry and
PCR analyses of the DNA from these tissues failed
to reveal the presence of either HSV-1 or 1716. Both
of these were successful phase I clinical trials, in
that they established the safety of stereotactic
intracranial inoculation of replication-competent,
genetically engineered HSV-1 for experimental
therapy of malignant glioma. This is no small feat,
recognizing the specific potential for the develop-
ment of encephalitis associated with this treatment
paradigm. At the highest doses employed in each
trial, no adverse effects were directly attributable
to the viral therapy. Notably, the inoculum was
4 log greater in the US study. Both trials used a
g134.5-null virus, with the difference between the
viruses being whether ICP6, the large subunit of
ribonucleotide reductase, was functional (1716) or
inactivated (G207). Each strategy has its own
advantages and disadvantages that have to be
weighed in terms of antitumor efficacy and patient
safety. While deletion of g134.5 creates a highly
attenuated virus in terms of neurovirulence,
such viruses can eventually evolve second-site
mutations to overcome the protein synthesis
shut-off phenotype. Given that the molecular basis
for attenuated neurovirulence of g134.5-deleted
HSV-1 is unresolved, certain safety precautions
should be built into the virus. This was in part
the basis for inactivation of ICP6 in G207. ICP6
inactivation also has the benefit of being hyper-
sensitive to ganciclovir in cases of adverse seque-
lae to HSV-1 inoculation.
However, g134.5-deleted viruses also do not
replicate to very high titers in experimental tumor
models. Inactivation of ICP6 would result only in a
less replication-competent virus. Since tumor
volume is the net effect of tumor cell division
and death, effective clinical responses would
require a virus whose replication outstrips tumor
growth. Deletion of viral thymidine kinase or
ribonucleotide reductase creates a replication-con-
ditional virus that targets proliferating cells such
that it can scavenge nucleotide precursors from the
cell. G207 may effectively replicate in the fraction
of cancer cells within a tumor that are actively
dividing. However, a significant proportion of
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cells within a tumor may not divide at a sufficient
rate to complement the virus in trans with nucleo-
tide precursors, leading to abortive infection. This
may explain in part why the Glasgow trial dose
escalated to 105 PFU with 1716 compared to
3 109 PFU with G207. Many questions have
arisen as a result of these trials. It appears that
toxic doses of 1716 or G207 were not attained,
implying that larger viral inocula could be toler-
ated. While a greater PFU inoculum of 1716 may be
given in a follow-up Glasgow trial, it is unlikely
that viral stocks made by good manufacturing
practices will allow for delivery of more than
3 109 PFU in future G207 clinical trials. Owing
to the location of these tumors, it is also difficult to
assess whether viral replication occurred within
the tumor. Tissue was available in these studies
following viral inoculation only when re-resec-
tions were performed or at autopsy. These phase
I trials, designed to established safety, will lead to
more in-depth trials that will begin to address
these questions as well as the most important
question of clinical efficacy.
NV1020
While the above phase I clinical trials were com-
pleted, a different attenuated, replication-compe-
tent genetically engineered HSV-1 mutant has
entered clinical trials for liver metastases from
colon adenocarcinoma (http://www.clinicaltrials.
gov). NV1020 is a clonal derivative of HSV-1
R7020. Genetically engineered HSV-1 R7020 is
an intertypic virus, initially constructed for immu-
nization against both HSV-1 and HSV-2 [34]. It
contains deletions of the internal inverted repeat
(one copy of a0, a4, g134.5, ORF O, and ORF P) as
well as UL23 (thymidine kinase), the UL24 promo-
ter, and UL56. Into the virus carrying these dele-
tions were inserted the UL23 encoding viral
thymidine kinase under the control of an a pro-
moter as well as the genes encoding the HSV-2
glycoproteins G, J, D, and I. R7020 was extensively
studied for genetic stability and safety in rodents,
rabbits, and primates [34,35]. Given that vaccines
are created with the utmost regard to safety for
healthy patients, this virus appears to satisfy the
safety criteria for a potential oncolytic agent for
patients with cancer. While this virus retains one
copy of the g134.5 gene, it is attenuated for neu-
roinvasiveness, and its attenuation appears to be
related to the absence of an internal inverted
repeat. Thus, non-CNS inoculation of the virus
may be safe. Initial studies with R7020 revealed
that it grew more robustly in tumor xenografts
than R3616 [36]. In experimental tumor models,
intratumoral injection of equivalent PFU of R7020
or R3616 resulted in the recovery of 25-fold
more R7020 than R3616. This result led to studies
demonstrating the antitumor efficacy of R7020
for multiple non-CNS tumors (i.e. head and
neck squamous cell carcinoma, prostate adenocar-
cinoma, pancreatic carcinoma, and metastatic
hepatic cancer) [37–39]. Additionally, the non-neu-
roinvasive phenotype of R7020 following intratu-
moral replication was proven in susceptible
murine models. Whereas wild-type HSV-1 injec-
tion of flank tumors resulted in both tumor regres-
sion and also death of the mouse, R7020 injection
resulted in tumor regression without death of the
mouse [37]. Given that NV1020 (R7020) is multi-
mutated, non-neuroinvasive, and replicates more
robustly than R3616 or G207, it provides a second
genetically engineered HSV-1 antitumor agent for
non-CNS tumors. NV1020 is currently in phase I
clinical trials for colon adenocarcinoma metastases
to the liver. Patients will receive a single intra-
hepatic arterial injection of R7020 for their liver
metastases, with dose escalation to evaluate safety.
Multimodality therapy with
replication-competent HSV-1 for
cancer therapy
While proof has been demonstrated in principle
for the use of genetically engineered replication-
competent HSV-1 for oncolysis in experimental
tumor models, strategies have evolved to further
improve the therapeutic ratio of these viruses. One
involves the insertion of therapeutic genes into the
virus genome, and the other involves combining
viral therapy with standard cancer therapies (i.e.
chemotherapy or radiotherapy). Such combina-
tions result in the destruction of tumor cells by a
variety of mechanisms, as well as interactive
effects of the therapies. Also, lower doses of each
therapy in combination may enhance tumor con-
trol while minimizing normal tissue toxicity
caused by the therapies. However, such approa-
ches, on the surface, appear counter-intuitive, in
that the adjuvant therapy may lead to destruction
of infected cells prior to the completion of the viral
lytic cycle, and thereby limit the efficacy of repli-
cation-competent viruses. Thus, it becomes impor-
tant to determine the impact of the additional
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therapy on the ability of the virus to replicate
within the tumor.
Foreign gene insertion within
replication-competent HSV-1
Immune modulation
Cancer immunotherapy, like gene therapy, has
been the focus of intense clinical investigations.
Many cancer patients are immunosuppressed, and
tumor cells have been shown to secrete immuno-
suppressive molecules (i.e. TGF-b and prostaglan-
dins); also, tumor-specific antigens have been
identified for certain tumors. However, systemic
administration of immune-stimulating cytokines
is accompanied by dose-limiting toxicity. Viral
vectors, on the other hand, offer the opportunity
to spatially restrict cytokine expression directly
within the inoculated tumor bed. Viral replication,
local overexpression of cytokines and tumor cell
debris following viral lysis may all combine to
result in a potent antitumor immune response.
This concept was shown in principle by the inser-
tion of interleukin-4 (IL-4) into g134.5-deleted
HSV-1 [40]. Cells infected with IL-4-encoding
virus showed a 1300-fold increase in production
of IL-4. Intracranial inoculation of this virus in a
syngeneic murine glioma model also resulted in an
increased accumulation of macrophages and CD8-
and CD4-positive T-cells, along with enhanced
survival.
IL-12 has also been inserted into g134.5-deleted
HSV-1 virus, M002 [41]. Certain known properties
of IL-12 may make it a better agent for immu-
notherapy. IL-12 is a heterodimer consisting of 35-
and 40-kDa subunits. The actions of IL-12 include
proliferation of cytotoxic T-cells and natural killer
cells, cell-mediated immunity (by promoting Th1
development), and antiangiogenesis. Since IL-12 is
a heterodimer, M002 was constructed with a
g134.5-deleted virus and insertion of IL-12 in a
single expression cassette, with the p40 and p35
subunits separated by an internal ribosomal entry
site. Infection of cells with M002 resulted in the
expression of physiologic levels of IL-12 [41].
Moreover, in a murine syngeneic model for neu-
roblastoma, M002 resulted in prolonged survival
and revealed an abundance of CD4þ and CD8þ T-
cells and macrophages compared to the parental
g134.5-deleted HSV-1.
In employing immunomodulation in conjunc-
tion with replication-competent HSV-1, the effects
of HSV-1 infection on immune evasion should be
dealt with. ICP47, the product of the US12 gene,
has previously been shown to block MHC class I
expression of antigenic peptides [42]. ICP47 binds
to the transporter associated with antigen proces-
sing (TAP) and prevents peptide translocation in
the endoplasmic reticulum and loading of MHC
class I molecules. In strategies employing replica-
tion-competent HSV-1 with immunomodulatory
cytokines for cancers, deletion of the US12 gene
may prove beneficial. Deletion of the US12 gene is
also reported to decrease neurovirulence (i.e.
enhance survival) in mice infected though the
cornea, a finding which may improve viral safety
[43]. Using the viruses in current clinical trials as a
backbone, US12 has been deleted from both G207
and NV1020 [19,44]. As mentioned above, deletion
of the US12 gene and placement of the US12 a
promoter in juxtaposition with the US11 gene
has been used to abrogate phosphorylation of
eIF-2a associated with g134.5-deleted virus
(G207), resulting in more robust viral replication
[19]. As a consequence of the deletion of US12,
MHC class I surface expression is not blocked in
infected cells [19]. A similar approach has been
studied with NV1020. The viruses NV1034 and
NV1042 do not produce ICP47, due to the insertion
of the Escherichia coli lacZ gene within the US12
gene, and encode either GM-CSF or IL-12, respec-
tively [44]. In studies using a syngeneic murine
squamous cell carcinoma model, pre-established
tumors injected with NV1042 (mIL-12 expressing)
had enhanced regression compared to the parental
virus, which does not encode mIL-12. Importantly,
these studies also demonstrated memory immu-
nity to the tumor from NV1042 treatment. Thus,
mice with established flank tumors treated with
NV1042, and rechallenged with the same tumor
cells in the contralateral flank, developed signifi-
cantly fewer tumors.
Prodrug-converting enzymes
This paradigm involves delivery of a gene encod-
ing a prodrug-converting enzyme (mammalian or
non-mammalian) to tumor cells, which is then
followed by systemic administration of a prodrug.
Given that the prodrug is relatively innocuous,
it circulates within the bloodstream and is con-
verted to a toxic metabolite in cells expressing the
prodrug-converting enzyme. This approach has
also been termed ‘suicide gene therapy’. Certain
drugs can diffuse out of the cell that encodes the
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prodrug-converting enzyme. Thus, neighboring
cells that have not been transduced with the pro-
drug-converting enzyme can also be killed by the
soluble toxic metabolite (bystander effect), greatly
increasing the utility of this treatment paradigm.
HSV-1 encodes one such enzyme, thymidine
kinase (HSV-1 tk). This enzyme has been exten-
sively studied in combination with ganciclovir or
acyclovir. HSV-1 tk has been delivered by numer-
ous transfection agents and has laboratory efficacy
for tumor cell destruction. Almost all current repli-
cation-competent HSV-1 viruses that are being
studied encode HSV-1 tk. This enzyme provides
a ‘safety net’, in that administration of ganciclovir
or acyclovir can inhibit viral replication and enable
cessation of therapy with replication-competent
HSV-1. Two prodrug-converting enzymes, cyto-
chrome P450 2B1 and cytosine deaminase, have
also been inserted in replication-competent HSV-1,
with the goal of improving tumor cell kill, while
not impairing the ability of the virus to replicate
[45,46].
Cytochrome P450 2B1 converts cyclophospha-
mide and ifosfamide to toxic metabolites. In con-
verting cyclophosphamide, cytochrome P450 2B1
produces phosphoramide mustard (a DNA alky-
lator) and acrolein (a protein alkylator). Normally,
cytochrome P450 2B1 is expressed in hepatocytes
but not in tumor cells, such that cyclophospha-
mide is activated in the liver, resulting in systemic
distribution of these toxic products to normal
tissues with high proliferative indices, gastroin-
testinal mucosa and hematopoietic cells. By trans-
ducing tumor cells with cytochrome P450 2B1,
elevated intratumoral concentrations of cyclopho-
sphamide metabolites may be achieved, resulting
in enhanced tumor cell kill with decreased normal
tissue toxicity. The replication-competent HSV-1
rRp450 was constructed by insertion of the rat
cytochrome P450 2B1 gene into the UL39 gene
locus, resulting in loss of expression of the viral
large subunit of ribonucleotide reductase (ICP6)
[45].
Cytosine deaminase (CD) is expressed by bac-
teria and fungi, but not in mammalian cells, and
deaminates cytosine to uracil. CD can therefore
convert non-toxic 5-fluorocytosine (5-FC) to the
common anticancer agent 5-fluorouracil (5-FU).
5-FU is metabolized to a deoxynucleotide mono-
phosphate (5-dUMP) and poisons thymidylate
synthetase, which inhibits DNA synthesis. 5-FUTP
produced from phosphorylation of 5-FU can
also get incorporated into RNA and disrupt
mRNA and rRNA function. Though 5-FU is an
effective cytotoxic agent with systemic toxicities,
the therapeutic window of this drug could be
enhanced by confining 5-FU production to the
tumor bed through the CD/5-FC combination.
5-FU is also freely diffusible, such that surround-
ing non-CD-transduced cells can be exposed to
5-FU. The replication-competent HSV-1 HSV1yCD
was created by insertion of the yeast CD gene
into the UL39 gene, thereby inactivating ICP6
[46].
By virtue of the inactivation of ICP6 in rRp450
and HSV1yCD, both viruses have a predilection
to replicate in tumor cells compared to normal
cells [8]. Treatment with either of these prodrug-
converting enzyme-containing viruses enhanced
tumor cell cytotoxicity and tumor xenograft regres-
sion upon administration of the prodrug [45–47].
Importantly, the toxic metabolites of cyclopho-
sphamide or 5-FC do not significantly attenuate
the ability of the virus to replicate, whereas treat-
ment with ganciclovir drastically reduced viral
replication [46,47].
Replication-competent HSV-1 combination
with standard cancer therapies
Many current cancer therapeutic regimens involve
the use of combinations of surgery, radiotherapy,
and chemotherapy. The application of replication-
competent genetically engineered HSV-1 in com-
bination with either radiotherapy or chemother-
apy has also been explored. As stated above, the
only proven beneficial therapy for GBM is the use
of radiotherapy in concert with surgery. Given that
radiotherapy is routinely employed for GBM as
well as in over 50% of all cancer patients, and
considering its ability to be specifically targeted
to the tumor bed, it may prove to be a useful
complement to intratumoral HSV-1 inoculation.
The combination of ionizing radiation with either
R3616 or R7020 has been shown to result in
enhanced tumor regression and survival in experi-
mental tumor models for gliomas or non-CNS
histologic tumor xenografts [36,37,48]. As for the
mechanism of enhanced tumor regression with
this combined therapy, studies indicate that ioniz-
ing radiation may result in enhanced viral replica-
tion and distribution of replication-competent
genetically engineered HSV-1 within experimental
tumor xenografts [36,48].
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A variety of chemotherapeutic agents have also
been tested in combination with replication-com-
petent HSV. The chemotherapeutic agent cisplatin
has been utilized in combination with G207 for
human squamous cell carcinomas [49]. Cisplatin
did not adversely affect viral growth, and in cer-
tain tumor cell xenografts, cisplatin combined with
G207 resulted in supra-additive effects on xeno-
graft regression. Mitomycin C in combination with
1716 for non-small cell lung cancer xenografts had
additive effects [50]. Finally, fluorodeoxyuridine
(FUdR) has been shown to enhance replication and
cytotoxicity of G207 in colorectal adenocarcinoma
cell lines [51]. The mechanism of action of FUdR
appears to aid G207 replication by targeting the
activity of cellular ribonucleotide reductase (RR).
As stated before, G207 is deleted in g134.5 and
lacks functional ICP6 (large subunit of ribonucleo-
tide reductase). One mechanism of action of FUdR
is inactivation of cellular thymidylate synthetase,
resulting in depletion of dTTP and imbalance of
intracellular deoxynucleotide pools. A conse-
quence of FUdR is the upregulation of cellular
RR activity. Thus, the upregulation of cellular
RR upon treatment with FUdR can aid in comple-
menting the ICP6 defect of G207.
With the apparent safety of 1716 and G207
demonstrated in the recently completed phase I
clinical trials, the addition of standard radiother-
apy or chemotherapeutic agents in future clinical
trials may be warranted. Such combinations of
standard cancer therapy with replication-condi-
tional virus also has a precedent in knowledge
gained with the ONXY-015 adenovirus. In a phase
II clinical trial of patients with recurrent head and
neck cancers, the virus proved especially beneficial
in combination with chemotherapy (cisplatin and
5-fluorouracil) [52]. While the mode of action of
enhanced tumor cell eradication in combination
with replication-competent HSV-1 is speculative
(except, perhaps, for FUdR), these therapies are
standard cancer treatments, and may allow for
enhanced therapeutic ratios, resulting in improved
clinical efficacy.
R E P L I C A T I O N - D E F E C T I V E H S V - 1
Given the relatively large genomic size of HSV-1, a
benefit of utilizing replication-defective HSV-1
over other viral transfection systems is the ability
to insert large and/or multiple foreign genes into
these vectors. Inherent neurotropism also provides
a means to deliver genes to neurons or other
postmitotic cells that are difficult to transduce
by other viral vectors. In addition, HSV-1 viruses
have a wide-range cell tropism, and the genome
remains extrachromosomal, thereby minimizing
the risk of genetic changes in the infected cell by
insertional mutagenesis. Replication-defective
HSV-1 mutants were initially categorized as either
helper virus dependent or independent. The
helper virus-dependent viruses are also termed
amplicons, and minimally consist of packaging
sequences (the a terminal repeats) and an origin
of viral DNA replication. Amplicons will not be
discussed in this review, and the reader is referred
to recent reviews on this topic [53,54]. Helper
virus-independent viruses (referred to here as
replication-defective HSV-1) have deletions in
one or more essential genes and can be grown
in cell lines that express the essential gene to
provide the gene product in trans. Recombination
to wild-type virus can be minimized by creating
cell lines with minimal essential gene coding frag-
ments that have no homology to the deleted virus
genome.
Replication-defective essential gene-deleted
vectors
To propagate HSV-1 mutants with deletions of
essential genes, cell lines are created to express
the deleted viral gene and provide it in trans to the
mutated virus, so that replication can proceed with
resultant mutant progeny. The advantages of this
system are two-fold. There is no risk of contam-
ination with helper viruses, and high viral titers can
be produced easily. Up to 40 kb of foreign DNA
could be inserted into such viruses, depending on
the deletion of non-essential genes as well. Two of
the immediate early genes of HSV-1 are essential,
a4 and a27. Deletion of either of these genes would
produce a potential replication-defective HSV-1 to
be used as a vector for gene delivery. However, it
was soon realized that mutant viruses harboring
deletions in either a4 or a27 were cytotoxic and
induced apoptosis of the infected cell, thereby
precluding their use as stable gene transfer vectors
[21,55–57]. While the absence of ICP4 or ICP27
production inhibits viral replication, certain viral
proteins (mainly the remaining immediate early)
are still produced by infection with these mutants.
Two strategies could be employed to circumvent
the problem with a single deletion virus. The first
 2002 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 8, 551–563
Advani et al Redirecting herpes simplex virus-1 for therapeutic applications 559
would be to attenuate the expression of the
remaining viral genes expressed in a single dele-
tion virus (assuming that expression of the remain-
ing a genes is toxic to the cell), and the second
would involve blocking the cytotoxicity of a single
deletion virus by insertion of a protective gene into
the mutant virus.
A virus deleted for a4 (d120) continues to pro-
duce the remaining a proteins (ICP0, ICP22, ICP27,
and ICP47) as well as a few other genes [58]. The
toxicity due to d120 could be in part due to the
expression of these genes. Since a gene transcrip-
tion is transactivated by the virion tegument pro-
tein VP16 (aTIF), an a4-null virus was created with
a mutation in VP16 [59]. This virus was less cyto-
toxic, with increased cell survival compared to an
a4-null virus. A more direct approach to address
the cytotoxicity of the a4-null virus would be the
systemic deletion of the remaining a genes. These
results showed that a virus deleted in a4, a22 and
a27, or a0, a4 and a27, had increased cell survival
compared to a virus deleted in a4 alone [58,60].
And when all five of the immediate early genes
were deleted, the viral vector exhibited almost no
cytotoxicity as measured by cell survival, provid-
ing an innocuous gene transfer vector [60].
The second approach to attenuating the cyto-
toxicity of a4-null viruses would be to protect the
infected cell from its apoptotic fate. The a4-null
viral mutant d120 has previously been shown to
induce apoptosis [21]. Apoptosis induced by d120
can be blocked by the overexpression of two pro-
teins, Bcl-2 or US3 (HSV-1-encoded viral kinase).
d120 infection of a cell line that overexpresses Bcl-2
did not result in apoptosis [22]. Also, baculoviral
delivery of the US3 blocked d120-induced mito-
chondrial cytochrome c release and procaspase 3
cleavage [61]. Therefore, a d120-based vector enco-
ding either of these genes may allow for gene
transfer without induction of apoptosis. However,
there is leaky late gene expression from d120 that is
likely to be toxic to the cell, which necessitates the
deletion of other viral a genes to create a non-toxic
vector.
The goal of such vector design is the ability to
infect cells and drive long-term gene expression of
a therapeutic gene. While a virus deleted in all five
a genes is not cytotoxic, CMV IE promoter-driven
foreign gene expression delivered with this virus
is also severely inhibited [60]. The CMV promoter
may not be suitable for such a mutant virus, since it
has been previously shown to be transcriptionally
repressed in HSV-1 mutants that did not express
immediate early proteins [62]. To circumvent this
problem, studies have been done with an HSV-1
virus deleted in a4, a22, and a27 [63]. Such a virus
was able to express the reporter lacZ gene driven
from either the CMV IE promoter or HSV-1 ICP0
promoter for up to 21 days after infection of neu-
rons in cell culture. The HSV-1 virus deleted in a4,
a22 and a27 has also been shown to be effective in
delivering neuroprotective genes in an animal
model. In a rat model for Parkinson’s disease, in
which death of neurons in the substantia nigra is
induced with the chemical 6-hydroxydopamine, a
replication-defective HSV-1 deleted in a4, a22 and
a27 encoding Bcl-2 driven by the CMV IE promoter
was able to significantly enhance neuronal survi-
val compared to the virus that does not encode Bcl-
2 [64]. While encouraging, this animal model is
problematic, since it induces fairly rapid death of
substantial nigra neurons, and the virus is given 1
week prior to the neuronal insult. It would be
beneficial to determine the length of time Bcl-2
can be expressed after viral inoculation. Studies
have begun to address the issue of how different
promoters temporally express transgenes in defec-
tive viruses. In an ICP4-null virus, nerve growth
factor (NGF) was placed under the control of either
the CMV IE promoter or the latency active pro-
moter 2 (LAP2). The CMV IE promoter maximally
expressed NGF 3 days post-infection, whereas the
LAP2 promoter had greater expression of NGF at
14 days post-infection of primary dorsal root gang-
lia cultures [65]. This result is intriguing in that it
suggests that the best way to prevent neuronal
insult in the short and long term would be to
employ a combination of viruses (or a single virus
with two expression cassettes) with both an imme-
diately active promoter and a promoter that would
transcribe at a later time. Thus, for immediate
protection, a CMV or HSV-1 IE promoter would
quickly transcribe the protective gene (days 1–7
post neuronal insult, for example), after which
transcription from the LAP promoter would pro-
tect during the following weeks.
Another advantage of replication-defective HSV
mutants is their ability to insert large genes or
multiple genes. A replication-defective HSV-1
has been deleted for 11.6 kb. It is deleted in the
a genes a4, a22, a27, and a47, ensuring decreased
vector toxicity, along with deletions in the genes
UL24, UL41, UL44, US10, and US11. One way to
enlarge the capacity of replication-defective HSV-1
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is by simultaneous deletion of non-essential viral
genes. In this multimutated HSV-1, genes encod-
ing IL-2, GM-CSF, B7.1, and LacZ or IFN-g were
inserted, for a total 12-kb insertion [66]. The four
genes were inserted as separate transcriptional
units and were simultaneously expressed in cell
culture upon infection of primary melanoma cells
for up to 1 week. Also, the rather large, 14-kb
dystrophin gene was placed into replication-defec-
tive HSV-1, for potential treatment of muscular
dystrophy [67]. The virus was able to express
dystrophin upon infection of muscle cells in cul-
ture, and in a dystrophin-deficient mouse model
(MDX), the virus was able to express dystrophin in
muscle cells at the site of viral inoculation. Inser-
tion of such a large single gene would be a rather
difficult task for other viral delivery systems.
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